Liyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liyun Zhang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Bang-Hui Shi
Department of Plastic Surgery, The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, People's Republic of China; and
1 shared publicationChun-Ye Chen
Department of Plastic Surgery, The Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, People's Republic of China; and
1 shared publication- Devin G. Peterson
Department of Food Science and Technology, Pelotonia Research Center, The Ohio State University, 2255 Kenny Rd, Columbus, Ohio 43210, United States
1 shared publication Dong-Lin Hao
Department of Rheumatism and Clinical Immunology, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China
1 shared publicationElizabeth Neuman
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
1 shared publication- Fenju Liu
State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Medical College of Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou 215123, China
1 shared publication
Latest Publications
- Open Access
- 31 July 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (7)
Systemic lupus erythematosus complicated with reversible posterior encephalopathy syndrome: a case report
A 28-year-old female patient was hospitalized primarily because of “intermittent fever for 28 days aggravated by systemic rashes, oral ulcer, and edema in both eyelids for 5 days.” During treatment, convulsions and loss of consciousness occurred. Magnetic resonance imaging (MRI) of the head revealed an abnormal signal with shadows in the bilateral frontal, parietal, temporal, and occipital lobes; cerebellar hemispheres; and basal nodes, with high signal intensity on T2 weighted imaging (T2WI), on fluid-attenuated inversion-recovery, and of the apparent diffusion coefficient and low signal intensity on T1WI and diffusion weighted imaging. Therefore, the patient was diagnosed with systemic lupus erythematosus (SLE) with reversible posterior encephalopathy syndrome (RPES). Intravenous high-dose methylprednisolone and cyclophosphamide were administered for blood pressure control, which effectively controlled the disease. Therefore, when patients with SLE and hypertension or renal insufficiency or those receiving high-dose methylprednisolone or immunosuppressants suddenly present with neurologic abnormalities, a diagnosis of RPES must be considered, and head MRI is the first choice for diagnosis of this disease. In terms of treatment, the blood pressure should be quickly controlled, and the primary disease should be aggressively treated.
- 31 July 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (7)
Open AccessSystemic lupus erythematosus complicated with reversible posterior encephalopathy syndrome: a case report
A 28-year-old female patient was hospitalized primarily because of “intermittent fever for 28 days aggravated by systemic rashes, oral ulcer, and edema in both eyelids for 5 days.” During treatment, convulsions and loss of consciousness occurred. Magnetic resonance imaging (MRI) of the head revealed an abnormal signal with shadows in the bilateral frontal, parietal, temporal, and occipital lobes; cerebellar hemispheres; and basal nodes, with high signal intensity on T2 weighted imaging (T2WI), on fluid-attenuated inversion-recovery, and of the apparent diffusion coefficient and low signal intensity on T1WI and diffusion weighted imaging. Therefore, the patient was diagnosed with systemic lupus erythematosus (SLE) with reversible posterior encephalopathy syndrome (RPES). Intravenous high-dose methylprednisolone and cyclophosphamide were administered for blood pressure control, which effectively controlled the disease. Therefore, when patients with SLE and hypertension or renal insufficiency or those receiving high-dose methylprednisolone or immunosuppressants suddenly present with neurologic abnormalities, a diagnosis of RPES must be considered, and head MRI is the first choice for diagnosis of this disease. In terms of treatment, the blood pressure should be quickly controlled, and the primary disease should be aggressively treated.
- Open Access
- 18 June 2021
- Published by Open Source Publications in Journal of Clinical Images and Medical Case Reports
- Vol. 2 (3)
Tuberculosis of bilateral ankles: Misdiagnosed as rheumatoid arthritis
The osteoarticular tuberculosis is a uncommon diease, which is accout for 0.1%-0.3% of Tuberculosis (TB). The involoment of foot and ankle is only 0.01%-0.03% of TB, particularly the bilateral feet and ankles are affected is extremely rare. Futhermore, its clinical manifestation is atypical and similar with autoimmune disorder, subacute or chronic pyogenic arthritis, osteochondrosis, benign bone tumors and so on, which conduce to the delay of its diagnose and therapy along with unfavourable prognosis. Here we present a case of a 52-year-old man with bilateral feet and ankles tuberculous arthritis, misdiagnosed successively Rheumatoid Arthritis (RA) and Poncet’s diease. It is hope that can enhance the alertness about osteoarticular tuberculosis. Keywords: Osteoarticular tuberculosis; ankle; foot; misdignose.
- 18 June 2021
- Published by Open Source Publications in Journal of Clinical Images and Medical Case Reports
- Vol. 2 (3)
Open AccessTuberculosis of bilateral ankles: Misdiagnosed as rheumatoid arthritis
The osteoarticular tuberculosis is a uncommon diease, which is accout for 0.1%-0.3% of Tuberculosis (TB). The involoment of foot and ankle is only 0.01%-0.03% of TB, particularly the bilateral feet and ankles are affected is extremely rare. Futhermore, its clinical manifestation is atypical and similar with autoimmune disorder, subacute or chronic pyogenic arthritis, osteochondrosis, benign bone tumors and so on, which conduce to the delay of its diagnose and therapy along with unfavourable prognosis. Here we present a case of a 52-year-old man with bilateral feet and ankles tuberculous arthritis, misdiagnosed successively Rheumatoid Arthritis (RA) and Poncet’s diease. It is hope that can enhance the alertness about osteoarticular tuberculosis. Keywords: Osteoarticular tuberculosis; ankle; foot; misdignose.
- Open Access
- 11 May 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (9) , 5199-5208
The source of ACE during scar formation is from both bone marrow and skin tissue
Angiotensin‐converting enzyme (ACE) has been found in the pathogenesis of various fibrosis diseases, and ACE inhibitor (ACEI) may affect wound healing and cutaneous fibrosis. However, there is no scientific evidence as to where the ACE is produced during scar formation. Whether it is from the cutaneous tissue or the bone marrow, or both remains unknown. In this study, we investigated the source of ACE using bone marrow transplantation in genetically modified mice, analyzed the inflammatory milieu and some growth factors in the middle of the wound healing period (4 d after the wound was induced). After having deleted the ACE from bone marrow or skin tissue, the wound/scar width in the low‐ACE groups were narrower than those in wild‐type (WT) controls. Loosely arranged collagen deposition and reduced vessel density were also detected in ACE‐deficient mice. Lower ACE levels during scar formation were also accompanied by lower levels of TGF‐β1. In the middle of the wound healing period, ACE levels affected the inflammatory cells significantly. In the mice with a deficiency in ACE, the expression of TGF‐β1 and TNF‐α decreased, but not that of IL‐4. Our findings indicate that both bone marrow and skin tissue release ACE during scar formation. Deleting either of them can affect the inflammatory cells and growth factors and reduce the expression of TGF‐β1, resulting in a decreased level of scarring.—Fang, Q.‐Q., Wang, X.‐F., Zhao, W.‐Y., Chen, C.‐Y., Zhang, M.‐X., Shi, B.‐H., Zhang, L.‐Y., Tan, W.‐Q. The source of ACE during scar formation is from both bone marrow and skin tissue. FASEB J. 32, 5199–5208 (2018). www.fasebj.org
- 11 May 2018
- Published by Wiley in The FASEB Journal
- Vol. 32 (9) , 5199-5208
Open AccessThe source of ACE during scar formation is from both bone marrow and skin tissue
Angiotensin‐converting enzyme (ACE) has been found in the pathogenesis of various fibrosis diseases, and ACE inhibitor (ACEI) may affect wound healing and cutaneous fibrosis. However, there is no scientific evidence as to where the ACE is produced during scar formation. Whether it is from the cutaneous tissue or the bone marrow, or both remains unknown. In this study, we investigated the source of ACE using bone marrow transplantation in genetically modified mice, analyzed the inflammatory milieu and some growth factors in the middle of the wound healing period (4 d after the wound was induced). After having deleted the ACE from bone marrow or skin tissue, the wound/scar width in the low‐ACE groups were narrower than those in wild‐type (WT) controls. Loosely arranged collagen deposition and reduced vessel density were also detected in ACE‐deficient mice. Lower ACE levels during scar formation were also accompanied by lower levels of TGF‐β1. In the middle of the wound healing period, ACE levels affected the inflammatory cells significantly. In the mice with a deficiency in ACE, the expression of TGF‐β1 and TNF‐α decreased, but not that of IL‐4. Our findings indicate that both bone marrow and skin tissue release ACE during scar formation. Deleting either of them can affect the inflammatory cells and growth factors and reduce the expression of TGF‐β1, resulting in a decreased level of scarring.—Fang, Q.‐Q., Wang, X.‐F., Zhao, W.‐Y., Chen, C.‐Y., Zhang, M.‐X., Shi, B.‐H., Zhang, L.‐Y., Tan, W.‐Q. The source of ACE during scar formation is from both bone marrow and skin tissue. FASEB J. 32, 5199–5208 (2018). www.fasebj.org
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , 34S
Safety and Efficacy of the Foley Balloon for Cervical Ripening During Induction of Labor in Women With Prior Cesarean [15C]
Induction of labor in women with prior cesarean is a safe alternative to repeat cesarean. Current evidence has not determined the best method for women who require cervical ripening. We sought to determine whether the use of the Foley balloon is comparable in safety and efficacy to oxytocin. We conducted a retrospective chart review of all women with prior cesarean undergoing induction between 1990 and 2015. We compared the vaginal delivery rate, maternal adverse event composite, and neonatal adverse event composite. The maternal composite included hemorrhage, infection, uterine rupture, and maternal death. The neonatal composite included 5m Apgar < 7, umbilical artery pH < 7, NICU admission, and neonatal death. Confounding variables, including Bishop score, previous vaginal delivery, gestational age, and presence of PROM, were identified by logistic regression. 66 women were induced by Foley balloon and 405 by oxytocin. The vaginal delivery rate was significantly less in the Foley balloon group compared to the oxytocin group (55% vs 75%, p=0.001). The rates of maternal and neonatal adverse events were equivalent (24% vs 15%, p=0.070; 11% vs 10%, p=0.86). Logistic regression determined that women with 3 or more deliveries (odds ratio 0.22 (CI 0.01, 0.05)) and gestational age greater than 36 weeks (OR 0.30 (CI 0.11, 0.80)) were associated with decreased likelihood of maternal adverse events; premature rupture of membranes (OR 3.91 (CI 1.93, 7.92)) was associated with increased likelihood of neonatal adverse events. With careful patient selection, Foley balloon is an acceptable induction method in women with prior cesarean.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , 34S
Safety and Efficacy of the Foley Balloon for Cervical Ripening During Induction of Labor in Women With Prior Cesarean [15C]
Induction of labor in women with prior cesarean is a safe alternative to repeat cesarean. Current evidence has not determined the best method for women who require cervical ripening. We sought to determine whether the use of the Foley balloon is comparable in safety and efficacy to oxytocin. We conducted a retrospective chart review of all women with prior cesarean undergoing induction between 1990 and 2015. We compared the vaginal delivery rate, maternal adverse event composite, and neonatal adverse event composite. The maternal composite included hemorrhage, infection, uterine rupture, and maternal death. The neonatal composite included 5m Apgar < 7, umbilical artery pH < 7, NICU admission, and neonatal death. Confounding variables, including Bishop score, previous vaginal delivery, gestational age, and presence of PROM, were identified by logistic regression. 66 women were induced by Foley balloon and 405 by oxytocin. The vaginal delivery rate was significantly less in the Foley balloon group compared to the oxytocin group (55% vs 75%, p=0.001). The rates of maternal and neonatal adverse events were equivalent (24% vs 15%, p=0.070; 11% vs 10%, p=0.86). Logistic regression determined that women with 3 or more deliveries (odds ratio 0.22 (CI 0.01, 0.05)) and gestational age greater than 36 weeks (OR 0.30 (CI 0.11, 0.80)) were associated with decreased likelihood of maternal adverse events; premature rupture of membranes (OR 3.91 (CI 1.93, 7.92)) was associated with increased likelihood of neonatal adverse events. With careful patient selection, Foley balloon is an acceptable induction method in women with prior cesarean.
- 31 July 2014
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 62 (33) , 8470-8477
Identification of Bitter Modulating Maillard-Catechin Reaction Products
The influence of thermally induced reaction products of a known dietary bitter compound, catechin, on bitterness perception was investigated. Catechin was reacted in low-moisture simple Maillard models (200 °C for 15 min) consisting of glycine and a reducing sugar (d-glucose, d-xylose, or d-galactose). Based on liquid chromatrography–mass spectrometry (LC-MS) isotopic labeling techniques, eight reaction products were identified and subsequently structurally elucidated by tandem LC-MS/MS and two-dimensional NMR analysis; six were report to be flavan-3-ol–spiro-C-glycosides reaction products. One of the spiro products was reported to significantly suppress the perceived bitterness intensity of a caffeine solution. Additionally, this specific spiro product was further identified in cocoa and reported to increase in concentration during bean roasting.
- 31 July 2014
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 62 (33) , 8470-8477
Identification of Bitter Modulating Maillard-Catechin Reaction Products
The influence of thermally induced reaction products of a known dietary bitter compound, catechin, on bitterness perception was investigated. Catechin was reacted in low-moisture simple Maillard models (200 °C for 15 min) consisting of glycine and a reducing sugar (d-glucose, d-xylose, or d-galactose). Based on liquid chromatrography–mass spectrometry (LC-MS) isotopic labeling techniques, eight reaction products were identified and subsequently structurally elucidated by tandem LC-MS/MS and two-dimensional NMR analysis; six were report to be flavan-3-ol–spiro-C-glycosides reaction products. One of the spiro products was reported to significantly suppress the perceived bitterness intensity of a caffeine solution. Additionally, this specific spiro product was further identified in cocoa and reported to increase in concentration during bean roasting.
- 12 April 2013
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 37 (1) , 125-131
CT-Guided Radioactive 125I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases
Purpose This study explored the clinical efficacy of CT-guided radioactive 125I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases. Methods Twenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive 125I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of 125I seeds. Results Follow-up period for this group of patients was 2–30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P < 0.05), and Karnofsky score rose dramatically (P < 0.05). Most patients reported pain relief 2–5 days after treatment. Follow-up imaging studies were performed 2 months later, which revealed CR in 7 patients, PR in 13 patients, SD in 3 patients, and PD in 2 patients. The overall effective rate (CR + PR) was 80 %. Median survival time was 25.5 months. Seven patients died of recurrent tumor; 16 patients died of multiorgan failure or other metastases. Two patients survived after 30 months follow-up. Two patients reported localized skin erythema 1 week postimplantation, which disappeared after topical treatment. Conclusions CT-guided radioactive 125I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes.
- 12 April 2013
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 37 (1) , 125-131
CT-Guided Radioactive 125I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases
Purpose This study explored the clinical efficacy of CT-guided radioactive 125I seed implantation in treating patients with symptomatic retroperitoneal lymph node metastases. Methods Twenty-five patients with pathologically confirmed malignant tumors received CT-guided radioactive 125I seed implantation to treat metastatic lymph nodes. The diameter of the metastatic lymph nodes ranged from 1.5 to 4.5 cm. Treatment planning system (TPS) was used to reconstruct the three-dimensional image of the tumor and then calculate the corresponding quantity and distribution of 125I seeds. Results Follow-up period for this group of patients was 2–30 months, and median time was 16 months. Symptoms of refractory pain were significantly resolved postimplantation (P < 0.05), and Karnofsky score rose dramatically (P < 0.05). Most patients reported pain relief 2–5 days after treatment. Follow-up imaging studies were performed 2 months later, which revealed CR in 7 patients, PR in 13 patients, SD in 3 patients, and PD in 2 patients. The overall effective rate (CR + PR) was 80 %. Median survival time was 25.5 months. Seven patients died of recurrent tumor; 16 patients died of multiorgan failure or other metastases. Two patients survived after 30 months follow-up. Two patients reported localized skin erythema 1 week postimplantation, which disappeared after topical treatment. Conclusions CT-guided radioactive 125I seed implantation, which showed good palliative pain relief with acceptable short-term effects, has proved in our study to be a new, safe, effective, and relatively uncomplicated treatment option for symptomatic retroperitoneal metastatic lymph nodes.